BPC-157 nasal spray: what is and is not known about intranasal use

The short answer: there is no published research on BPC-157 nasal spray. We found no study, in animals or in people, that gave BPC-157 through the nose and measured how much was absorbed or whether it did anything. A 2026 review of the peptide's development record describes preclinical activity by oral, injected, and topical routes; intranasal use is not among them. [1] Nasal sprays sold today rest on the injected and oral animal literature, plus the assumption that a nose works as well as a needle.

That assumption is testable, and for approved nasal peptide drugs it was tested. Here is what is known, what is not, and what a BPC-157 nasal spray would have to show.

Is there any research on BPC-157 nasal spray?

Not directly. The only indexed study we found that involves BPC-157 and the nose is a 1997 rat experiment on rhinitis. Researchers applied capsaicin inside rats' noses to inflame the lining, after pretreating them with BPC-157 or saline. BPC-157 reduced mast cell infiltration at 1 hour and, at the higher dose, reduced white blood cell infiltration in the nasal lining. [2]

The important detail is the route. The BPC-157 in that study was injected into the abdomen, not sprayed into the nose. [2] It tells you something about BPC-157 and nasal inflammation in rats. It tells you nothing about nasal delivery.

The published human reports, three small uncontrolled pilot studies, used injection into the knee, injection into the bladder wall, and intravenous infusion. [3] None used a nasal spray.

Why is BPC-157 sold as a nasal spray?

Nasal sprays avoid needles, which is most of their appeal. Some peptides are sold as nasal products because they have nasal clinical data behind them; our posts on semax nasal spray and selank nasal spray cover what those intranasal studies measured, and the entity pages for semax and selank grade the evidence. BPC-157 does not have that history. Its research was built on injections, drinking water, and creams in rodents. [1]

There is a second reason the nasal route matters for BPC-157 specifically: its half-life. In rats and dogs, injected BPC-157 was eliminated with a half-life under 30 minutes and broken down into small fragments and amino acids. [4] A nasal product would have to be absorbed quickly enough, and in enough quantity, to beat that clearance. No one has measured whether it is.

What does a nasal peptide have to prove?

Some approved peptide drugs are given through the nose, so the route can work. Desmopressin, a synthetic analog of the hormone vasopressin, is approved as a nasal spray as well as tablets and injection. [6] Salmon calcitonin is approved as a once-daily nasal spray for postmenopausal osteoporosis. [7] See the desmopressin and calcitonin pages for their label facts.

Each of those products was approved on its own human data. Nasal calcitonin, for example, was tested in a 5-year randomized trial of postmenopausal women with osteoporosis, where one dose reduced new vertebral fractures versus placebo. [8] For a nasal BPC-157 product, the equivalent questions have not been asked:

1. Absorption. How much of a sprayed dose reaches the blood, and how fast?
2. Local tolerance. Does repeated spraying irritate or damage the nasal lining?
3. Effect. Does a nasal dose change any outcome that matters, compared with placebo?

Until those are answered in people, a BPC-157 nasal spray is an untested delivery method for an untested drug.

BPC-157 nasal spray vs injection: is one better?

There is no basis for choosing one over the other, because neither has been measured in people. The only formal absorption data come from animals given intramuscular injections: about 14% to 19% of the dose reached the blood in rats and 45% to 51% in dogs. [4] Those figures vary more than threefold between two species on the same route, which shows how little they predict for a different route in a third species.

The 2026 development review put it plainly: BPC-157's human pharmacokinetic profile remains critically under-characterized, and no pharmaceutical-grade formulation has been validated for any route. [1] Claims that a spray is "just as effective" as an injection, or "better absorbed" than a capsule, are not backed by a measurement.

Does BPC-157 nasal spray reach the brain?

Nasal sprays are often marketed with "nose to brain" claims, meaning the peptide supposedly travels from the upper nose into the brain. For BPC-157, that has never been tested.

The brain claims borrow from rodent studies. The discovering group's reviews describe effects on dopamine and serotonin systems, behavior, and brain injury in rats and mice, after BPC-157 was injected or given in drinking water. [5] Those are animal findings from other routes. No study has shown that BPC-157 sprayed into the nose reaches the brain in any species.

BPC-157 nasal spray side effects: what is unknown

There are no systematic human safety data for BPC-157 by any route. A 2025 systematic review found no clinical safety data at all; its reassurance comes from preclinical safety studies. [9] For a nasal product, that gap is wider still, since no study has looked at the nasal lining after repeated use.

The larger practical risk is the product itself. Reviewers of unregulated peptides flag contamination, manufacturing impurities, and inaccurate content as major hazards, independent of what the peptide does. [10] A nasal spray adds preservative, pH, and sterility questions, and none of these is verified for products sold outside a pharmacy.

Is BPC-157 nasal spray legal?

BPC-157 is not an FDA approved drug in any form. FDA's Pharmacy Compounding Advisory Committee recommended it for the 503A bulks list in July 2026. [11] That recommendation is advisory: until FDA publishes a final rule, BPC-157 is not on the list, and a 503A pharmacy has no federal basis to compound it from bulk, as a spray or any other form. [12] Follow the rule on the BPC-157 regulatory timeline and check the state legal guides for pharmacy board rules.

Sprays sold as research chemicals are not lawful for human use. There is no lawful price to compare; the BPC-157 cost page explains why. BPC-157 is prohibited at all times for athletes subject to WADA testing. [13]

What would change this answer

A registered study that sprays BPC-157 into the nose and measures blood levels would be the first real data point. We will update this post when one is published. Until then, the evidence for BPC-157 by any route is summarized in our review of BPC-157 human studies, the oral forms are covered in oral BPC-157, and if a lawful route opens after the FDA rule, how to get peptides prescribed explains how a prescriber and pharmacy would handle it. Our peptide therapy explainer covers how clinics sell peptides that are not yet listed.